Generation Bio Co GBIO Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-7,500

Price:

--
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-600

Price:

$34.96
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-500

Price:

$34.12
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,900

Price:

$33.18
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,500

Price:

$32.29
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

7,500

Price:

$4.59
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Zimmermann Tracy

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,500

Price:

--
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Zimmermann Tracy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,500

Price:

$33.09
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Zimmermann Tracy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,500

Price:

$4.59
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Stanton Matthew

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-5,630

Price:

--

Filings by filing date

Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-7,500

Price:

--
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-600

Price:

$34.96
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-500

Price:

$34.12
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,900

Price:

$33.18
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-3,500

Price:

$32.29
Jan 15, 2021 (filed on Jan 20, 2021)

Insider Name:

Angelino Mark D.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

7,500

Price:

$4.59
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Zimmermann Tracy

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,500

Price:

--
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Zimmermann Tracy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,500

Price:

$33.09
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Zimmermann Tracy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,500

Price:

$4.59
Jan 14, 2021 (filed on Jan 15, 2021)

Insider Name:

Stanton Matthew

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-5,630

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	301 BINNEY STREET CAMBRIDGE MA 02142
Tel:	N/A
Website:	https://generationbio.com
IR:	See website

Key People

Cameron Geoffrey McDonough President, Chief Executive Officer, Director	Matthew Norkunas Chief Financial Officer	Mark Angelino Chief Operating Officer
Matthew Stanton Chief Scientific Officer	Douglas Kerr Chief Medical Officer	Tracy Zimmermann Chief Development Officer

Business Overview

Generation Bio Co. is a genetic medicines company. The Company is developing a class of gene therapy utilizing its non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The Company's non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The Company is developing gene therapies to provide targeted delivery of genetic payloads that include multiple genes to a range of tissues of diseases. The Company is also engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient's life. The Company is a preclinical stage company and have not identified a product candidate.

Financial Overview

For the nine months ended 30 September 2020,Generation Bio Co revenues was not reported. Net losstotaled to $56.3M.

Employees:	85 as of Apr 30, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$1,369M as of Sep 30, 2020
Annual revenue (TTM):	N/A
EBITDA (TTM):	N/A
Net annual income (TTM):	N/A
Free cash flow (TTM):	N/A
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	54,516,475 as of Jan 6, 2021
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Generation Bio Co (OQ:GBIO)